Navigation Links
Jubilant and Endo Pharmaceuticals Announce Successful Delivery of Early Milestones in Collaborative Discovery Program

BANGALORE, India, February 9, 2012 /PRNewswire/ --

Jubilant Biosys Ltd., a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd., announced today that they have achieved an early stage milestone in one of their collaborative programs with Chadds Ford, Pa., USA-based Endo Pharmaceuticals that has nominated a candidate into full development. The novel molecule, targeting cancer, is anticipated to go into clinical trials by late 2012. Jubilant and Endo will continue the collaboration in the development phase as well.  

The multi-target collaboration that began three years ago focuses on Best in Class differentiated therapies to address the unmet needs of cancer patients worldwide.  The collaboration has since delivered multiple milestones across the discovery phase.  Endo will pursue development and commercialization of the compound, while Jubilant becomes eligible to receive development milestones.

"We are very pleased and elated with this successful outcome, which is a result of the excellent collaboration between the scientists at Endo and Jubilant," said Sri Mosur, CEO & President, Global Drug Discovery and Development, Jubilant. "Jubilant has pioneered from India, a business model based on shared risk that enables it to demonstrate the differentiated and novel outcomes that Jubilant scientists are able to deliver through accelerated and affordable innovation to its many collaborators."

Sandeep Gupta, Endo Pharmaceuticals, Senior Vice President, Discovery & Early Development , said, "I congratulate the Jubilant and Endo teams on achieving this important milestone. It was their outstanding collaborative work and ingenuity that enabled nomination of a development candidate ahead of schedule in less than two years since inception of this program. Initiation of this development program further validates Endo's unique collabrative drug discovery approach which aims to address unmet medical needs and improve patient outcomes."  

About Us

Jubilant Biosys Ltd. is a Bengaluru based subsidiary of Jubilant Life Sciences Ltd, headquartered in Noida, India. Jubilant Biosys, provides integrated drug discovery and development solutions to the global pharmaceutical industry. It is a pioneer in collaborative discovery research and development and is engaged in multiple partnerships with global pharmaceutical industry in therapeutic areas of Oncology, CNS and CVMED.

Contact For Business Queries

Narendra Kumar

SOURCE Jubilant Biosys Ltd and Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jubilant HollisterStier Allergy Launches Allergy Industry Insights Educational Webinar Series
2. Jubilant and AstraZeneca Announce Successful Delivery of Early Milestones in Drug Discovery
3. Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture
4. Jubilant Enters Research Collaboration With AstraZeneca
5. Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models
6. Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain
7. Prismic Pharmaceuticals Acquires Scaristas Exclusive License to Amarins Omega-3 Patents for CNS Disorders
8. Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
9. Cadence Pharmaceuticals Announces Voluntary Recall of One Lot of OFIRMEV® (Acetaminophen) Injection
10. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
11. Generic Pharmaceuticals Market - A Global Analysis
Post Your Comments:
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/12/2017)... Pa. , Oct. 12, 2017 ... leader in innovative solutions for injectable drug administration, today ... before the market opens on Thursday, October 26, 2017, ... the results and business expectations at 9:00 a.m. Eastern ... (U.S.) or 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... Fla. (PRWEB) , ... October 12, 2017 , ... IsoComforter, ... therapy products, announced today the introduction of an innovative new design of the shoulder ... pad so you get maximum comfort while controlling your pain while using cold therapy. ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
(Date:10/12/2017)... Mich. (PRWEB) , ... October 12, 2017 , ... ... has been named one of Michigan’s 2017 Best and Brightest in Wellness® by ... Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to ...
Breaking Medicine News(10 mins):